SBIR/STTR Research Award

Phage Displayed Antibodies to C. botulinum toxin A

Award identifier e1226de3d006c0eec2a2c30f683d3eab526fb862e2f72c885bbd6acaef43bc34Awarding agency Department of Defense · Army

Award amount

$597,887

Program and phase

SBIR · Phase II

Award year

1996

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Defense
Branch
Army
Recipient company
HAWAII BIOTECH, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
ECJKEEFL4L51
Solicitation number
Not reported
Topic code
Not reported

Research abstract

The neurotoxins of Clostridium botulinum are the most lethal proteins known. The bacterium is ubiquitous, and thus rapid, reliable, sensitive, and cost-effective assays are needed to detect the toxin. Current immunoassays provide a rapid means to detect the neurotoxin. Their sensitivity, however, is limited by the affinity of the detecting antibody. The objective of this research, therefore, is to develop high-affinity anti-botulinal antibody through recombinant DNA technology. During Phase I, we will take a two pronged approach to generate recombinant botulinal antibodies. First, we will construct a phage-display heavy and light chain variable gene combinatorial library from a botulinal toxin A hyperimmunized animal. Bacteriophage displaying the neurotoxin reactive antibody fragments will be affinity selected and clonally isolated for subsequent analysis. As the combinatorial library may not represent in vivo occurring heavy-light chain combinations or all anti-toxin A immunoglobulin classes, we will in the second approach produce monoclonal antibodies (Mabs) by traditional hybridoma techniques, following which the encoding cDNAs will be cloned. In future work, the cDNAs from the isolated antibody fragment-displaying phage and from selected Mabs will be engineered for higher affinity recombinant antibodies, providing an invariant, stable, and inexpensive immunoassay reagent.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

103 SBIR/STTR records share this UEI (1983–2024). Reported award amounts total $40,917,853. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense, National Science Foundation, Department of Agriculture

Agency intelligence

Department of Defense

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.